WHO Introduces HPV Single-Dose Vaccine to Boost Cervical Cancer Elimination Efforts

By João L. Carapinha

October 6, 2024

The article from the World Health Organization (WHO) titled “WHO adds an HPV vaccine for single-dose use” highlights important advancements in the global initiative to combat cervical cancer through HPV vaccination, specifically through the introduction of a new single-dose HPV vaccine (SD-HPV Vac). This milestone aims to transform how girls are vaccinated against cervical cancer, particularly in regions with limited access to healthcare. Here are the key points:

New Single-Dose HPV Vaccine

The WHO has prequalified a fourth HPV vaccine product, Cecolin®, for use in a single-dose schedule. This decision is based on new data that meets the criteria set out in the WHO’s 2022 recommendations for alternative, off-label use of HPV vaccines in single-dose schedules.

Impact on Supply and Accessibility

The addition of this HPV vaccine will help address the ongoing global supply challenges for HPV vaccines, which have been hampered by shortages since 2018. This will enable more girls to be vaccinated against cervical cancer, particularly in low- and middle-income countries.

Global Strategy for Cervical Cancer Elimination

The WHO aims to have 90% of girls fully vaccinated with the HPV vaccine by the age of 15 as part of its global strategy for cervical cancer elimination. The single-dose HPV vaccine is expected to facilitate achieving this target.

Public Health Benefits

Cervical cancer is a preventable disease, with over 95% of the 660,000 annual cases globally caused by HPV. Every two minutes, a woman dies from cervical cancer, with 90% of these deaths occurring in low- and middle-income countries. The new SD-HPV Vac will help reduce these alarming statistics.

Funding and Commitments

There has been significant funding committed towards the elimination of cervical cancer. This includes nearly US$ 600 million from various partners, such as the Bill & Melinda Gates Foundation (US$ 180 million), UNICEF (US$ 10 million), and the World Bank (US$ 400 million).

Implementation and Coverage

As of September 10, 2024, 57 countries are implementing the HPV vaccine schedule, up from 37 countries in 2023. The adoption of the SD-HPV Vac schedule has resulted in at least 6 million additional girls being reached with HPV vaccines in 2023.

Technical and Regulatory Aspects

The single-dose use indication for Cecolin® is included in the second edition of WHO’s technical document on considerations for HPV vaccine product choice. Public health advisory bodies can recommend “off-label” use of vaccines when supported by data and clear public health benefits, until manufacturers update their labels.

Overall, the introduction of the SD-HPV Vac marks a significant step forward in the global effort to eliminate cervical cancer, enhancing vaccine accessibility and addressing supply challenges effectively.

Reference url

Recent Posts

modifiable risk factors
        

Targeting Shared Risk Pathways to Prevent Stroke, Dementia, and Depression

🧠 What if addressing just a few key lifestyle factors could significantly reduce the risk of stroke, dementia, and depression in older adults?

A recent systematic review has identified 17 **modifiable risk factors**, revealing the interconnected nature of these age-related brain diseases and offering crucial insights for preventive strategies. By focusing on aspects such as blood pressure management, nutrition, and physical activity, we can enhance quality of life for our aging population.

Dive into the article to explore how these findings could shape future healthcare models.

#SyenzaNews #HealthEconomics #HealthcareInnovation #DigitalTransformation

drug price regulation
      

Navigating Drug Price Regulation: Evaluating the Executive Order’s Potential Impacts and Challenges

💊 Curious about the future of drug pricing in the U.S.?

The recent executive order aims to tackle escalating prescription drug costs through measures like international reference pricing and enhanced transparency. However, the implications of these policies could be more complex than anticipated, with potential risks to market access and innovation.

Dive into the article for a detailed analysis of how these regulations could shape the pharmaceutical landscape and what it means for healthcare access in the U.S.

#SyenzaNews #pharmaceuticals #healthcarepolicy

AI Patient Education
       

AI Patient Education: Evaluating ChatGPT and Gemini for Pediatric Condition Materials

🤔 Are AI solutions ready to revolutionize pediatric patient education?

A recent study compared ChatGPT and Gemini in generating educational materials for common pediatric conditions, revealing intriguing insights into content depth, readability, and reliability. While both tools have their merits, there’s significant room for improvement in making AI-generated content accessible and effective for all families.

Curious to learn more about the implications for health literacy and the future of AI in healthcare? Click to read the full article!

#SyenzaNews #AIinHealthcare #HealthTech #DigitalTransformation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.